GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children From 6 to 35 Months of Age
- Conditions
- Influenza
- Interventions
- Biological: FluLaval® QuadrivalentBiological: Fluzone®
- First Posted Date
- 2013-11-03
- Last Posted Date
- 2018-09-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 316
- Registration Number
- NCT01974895
- Locations
- 🇺🇸
GSK Investigational Site, Fort Worth, Texas, United States
Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors
- Conditions
- CancerNeoplasms
- Interventions
- Biological: GSK2849330
- First Posted Date
- 2013-10-21
- Last Posted Date
- 2019-07-01
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 29
- Registration Number
- NCT01966445
- Locations
- 🇳🇱
GSK Investigational Site, Rotterdam, Netherlands
A Study to Evaluate a Skeletal-muscle Microbiopsy Technique With Dynamic Proteomic Measurement in Healthy Male Volunteers
- Conditions
- Cachexia
- Interventions
- First Posted Date
- 2013-10-14
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 20
- Registration Number
- NCT01962454
- Locations
- 🇺🇸
GSK Investigational Site, Durham, North Carolina, United States
A Relative Bioavailability Study of Fluticasone Furoate and Levocabastine
- Conditions
- Rhinitis, Allergic, Perennial and Seasonal
- Interventions
- Drug: FF/LEV FDCDrug: FFDrug: LEV
- First Posted Date
- 2013-10-14
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 30
- Registration Number
- NCT01962467
- Locations
- 🇦🇺
GSK Investigational Site, Randwick, New South Wales, Australia
An Efficacy Study of Stain Control of a 67% Sodium Bicarbonate Containing Toothpaste on Chlorhexidine Tooth Staining
- Conditions
- Oral Hygiene
- Interventions
- First Posted Date
- 2013-10-14
- Last Posted Date
- 2015-03-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 160
- Registration Number
- NCT01962493
- Locations
- 🇬🇧
Intertek 4-Front Research - Widnes, Widnes, Cheshire, United Kingdom
🇬🇧Intertek - Manchester Science Park, Manchester, United Kingdom
🇬🇧Intertek - Maldon (formerly 4 Front Research Ltd), Maldon, Essex, United Kingdom
This Will be an Open-label, Three-period, Fixed-sequence Study to Evaluate the Drug-drug Interaction, Pharmacokinetics and Safety of Dutasteride and Tamsulosin When Administered Alone and In-combination in Chinese Healthy Male Volunteers. The Study Will Last Approximately Eleven Weeks. Blood Samples
- First Posted Date
- 2013-10-08
- Last Posted Date
- 2018-06-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 24
- Registration Number
- NCT01957189
- Locations
- 🇨🇳
GSK Investigational Site, Shanghai, China
Efficacy of Topical Indomethacin Patch Over Placebo in Ankle Sprain Pain Relief
- First Posted Date
- 2013-10-08
- Last Posted Date
- 2015-06-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 270
- Registration Number
- NCT01957215
- Locations
- 🇨🇳
Changzhou NO.2 People?s Hospital, Changzhou, Jiangsu, China
🇨🇳Zhongda Hospital Southeast University, Nanjing, Jiangsu, China
🇨🇳The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: FFDrug: VIDrug: UMECDrug: Placebo
- First Posted Date
- 2013-10-08
- Last Posted Date
- 2017-11-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 619
- Registration Number
- NCT01957163
- Locations
- 🇷🇴
GSK Investigational Site, Timisoara, Romania
Study Evaluating the Effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder Compared With Vilanterol (VI) Inhalation Powder on Bone Mineral Density (BMD) in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2013-10-08
- Last Posted Date
- 2019-04-10
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 283
- Registration Number
- NCT01957150
- Locations
- 🇪🇸
GSK Investigational Site, Salamanca, Spain
A Proof of Concept Study to Assess Effect of Fluticasone Furoate (FF)/Levocabastine Fixed Dose Combination (FDC) Compared With Levocabastine and FF Alone in Subjects With Allergic Rhinitis (AR)
- Conditions
- Rhinitis, Allergic, Perennial and Seasonal
- Interventions
- First Posted Date
- 2013-10-08
- Last Posted Date
- 2017-01-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 71
- Registration Number
- NCT01957202
- Locations
- 🇦🇹
GSK Investigational Site, Vienna, Austria